Aurobindo Pharma Ltd. — Investor Relations & Filings
Aurobindo Pharma Ltd. focuses on the development, manufacturing, and commercialization of generic formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning key therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics. With a strong emphasis on vertical integration, the organization manages a comprehensive supply chain from basic chemicals to finished dosage forms. It operates advanced research and development centers and manufacturing facilities that comply with international regulatory standards. The company serves a broad international market, providing cost-effective healthcare solutions through an extensive pipeline of Abbreviated New Drug Applications (ANDAs) and a robust distribution network.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Submission of copy of post buyback public advertisement pertaining to buyback of shares of the Company. | 2026-05-08 | English | |
| Copy of Newspaper Publication | 2026-05-08 | English | |
| General Updates | 2026-05-06 | English | |
| General Updates | 2026-05-04 | English | |
| General Updates | 2026-05-01 | English | |
| Retirement | 2026-04-30 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44721770 | Submission of copy of post buyback public advertisement pertaining to buyback of shares of the Company. | 2026-05-08 | English | ||
| 44217262 | Copy of Newspaper Publication | 2026-05-08 | English | ||
| 42179224 | General Updates | 2026-05-06 | English | ||
| 42199843 | General Updates | 2026-05-04 | English | ||
| 42214588 | General Updates | 2026-05-01 | English | ||
| 42170714 | Retirement | 2026-04-30 | English | ||
| 42178621 | Copy of Newspaper Publication | 2026-04-22 | English | ||
| 42188705 | Buyback | 2026-04-21 | English | ||
| 42205116 | Press Release | 2026-04-17 | English | ||
| 42209861 | Press Release | 2026-04-17 | English | ||
| 42174544 | General Updates | 2026-04-15 | English | ||
| 42197336 | Copy of Newspaper Publication | 2026-04-11 | English | ||
| 42167296 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | ||
| 42186093 | Copy of Newspaper Publication | 2026-04-08 | English | ||
| 42190470 | Press Release | 2026-04-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
DAIICHI SANKYO COMPANY, LIMITED
A global healthcare company that researches and develops no…
|
4568 | JP | Manufacturing |
|
Daito Pharmaceutical Co., Ltd.
Integrated manufacturer of APIs and finished drugs for gene…
|
4577 | JP | Manufacturing |
|
Dare Bioscience, Inc.
A clinical-stage biopharmaceutical company advancing innova…
|
DARE | US | Manufacturing |
|
Dawnrays Pharmaceutical (Holdings) Limited
Develops, manufactures, and sells non-patented cephalospori…
|
2348 | HK | Manufacturing |
|
Day One Biopharmaceuticals, Inc.
Commercial-stage company developing targeted cancer therapi…
|
DAWN | US | Manufacturing |
|
DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology…
|
DBV | FR | Manufacturing |
|
DBV Technologies S.A.
A clinical-stage company developing epicutaneous immunother…
|
DBVT | US | Manufacturing |
|
D&D Pharmatech Inc.
Clinical-stage biopharma developing GLP-1 therapies for met…
|
347850 | KR | Manufacturing |
|
Deccan Health Care Limited
Develops and manufactures nutraceuticals, cosmeceuticals, a…
|
542248 | IN | Manufacturing |
|
Dechra Pharmaceuticals PLC
A global specialist in veterinary pharmaceuticals and relat…
|
DPH | GB | Manufacturing |
Aurobindo Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61251/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61251 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61251 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61251 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61251}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aurobindo Pharma Ltd. (id: 61251)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.